Date: 2014-03-03
Type of information: Production agreement
Compound: BC-821
Company: Cobra Biologics (UK - Sweden) BioCancell (Israel)
Therapeutic area: Cancer - Oncology
Type agreement: manufacturing
production
Action mechanism: BC-821 is a potential therapeutic product that penetrates cancerous cells and activates the synthesis of DTA under the control of H19 and /or P4 promoter of the target gene IGF2. Both H19 and P4-IGF2 transcription factors are expressed only in cancerous cells. This double-promoter method has the potential to reach a large patient population, as patients expressing either of the target genes will be treatable. An international patent application (PCT) for this product was filed by BioCancell in 2008.
Disease:
Details: * On March 3, 2014, Cobra Biologics, a contract manufacturer of clinical and commercial scale biologics and pharmaceuticals, and targeted cancer therapy company BioCancell have announced an agreement to manufacture BioCancell’s BC-821 cancer drug for clinical trials. BioCancell’s Phase I clinical trial for BC-82 is scheduled to commence in 2015. Cobra will provide GMP manufacture of BC-821 plasmid DNA, and fill and finish the product in accordance with aseptic manufacturing procedures before releasing it for clinical trials.
Financial terms:
Latest news:
